科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一,在亚利桑那州、佛罗里达州和明尼苏达州都有院区。医务人员掌握数几十种专业技能,齐心协力,确保高品质治疗与成功康复。

治疗此病症的医生

编辑搜索过滤条件
close

缩小搜索范围

重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. J.C. C. Villasboas Bisneto, M.D.

    J.C. C. Villasboas Bisneto, M.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域:

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Lymphoma, Follicular lymphoma

  2. Yucai Wang, M.D., Ph.D.

    Yucai Wang, M.D., Ph.D.

    1. Hematologist / Oncologist
    2. Hematologist
    1. Rochester, MN
    擅长领域:

    CAR-T cell therapy, Chronic lymphocytic leukemia, Diffuse large b-cell lymphoma, Mantle cell lymphoma, Non-Hodgkin lymp...homa, Small lymphocytic lymphoma, Follicular lymphoma, Hodgkin lymphoma

  3. Thomas E. Witzig, M.D.

    Thomas E. Witzig, M.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域:

    Multiple myeloma, B-cell lymphoma, Non-Hodgkin lymphoma, T-cell lymphoma, Small lymphocytic lymphoma, Follicular lympho...ma, Hodgkin lymphoma

  4. Saurabh S. Zanwar, M.B.B.S.

    Saurabh S. Zanwar, M.B.B.S.

    1. Hematologist
    1. Rochester, MN
    擅长领域:

    Bone marrow transplant, CAR-T cell therapy, Multiple myeloma, Amyloidosis, POEMS syndrome, Waldenstrom macroglobulinemia

研究

妙佑医疗国际在非霍奇金淋巴瘤研究方面处于国际领先地位。

非霍奇金淋巴瘤研究与妙佑医疗国际综合癌症中心合作开展。美国国家癌症研究所为妙佑医疗国际综合癌症中心提供资助并将其指定为综合癌症中心。这一称号是对该机构在癌症预防、诊断和治疗方面的卓越科学成就和多学科资源的认可。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际的医生在非霍奇金淋巴瘤领域的著述目录

Research Profiles

Nov. 07, 2025

Living with 非霍奇金淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

suzie71
I've had CML for 20 years and want to encourage others

112 Replies Wed, Jan 28, 2026

mjlandin
Does anyone else have MGUS?

1124 Replies Wed, Jan 28, 2026

jak2mpnpositive
I have JAK2 ET and MPN: Anyone else have these symptoms?

98 Replies Wed, Jan 28, 2026

See more discussions